Abstract
The aim of the study was to evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) drug dapoxetine in delaying ejaculation in patients with premature ejaculation (PE). A total of 212 potent men with PE were randomly assigned to receive 30 mg orally dapoxetine (group 1, N=106) twice daily or similar regimen of placebo (group 2, N=106) during a 12-week period for each agent. Pretreatment evaluation included history and physical examination, geometric mean intravaginal ejaculatory latency time (IELT, primary outcome measure), and International Index of Erectile Function (IIEF). The efficacy of two treatments was assessed every 2 weeks during treatment, at the end of study, and in 3-month follow-up after cessation of treatment. We measured geometric mean IELT. Thus, the IELT values were logarithmically transformed before statistical analysis, and the results are reported as fold increases from baseline with associated 95% confidence intervals (CI). The independent sample two-tailed t-test was used to compare the IELTs. At the end of 12-week treatment, the dapoxetine group had a 2.9- (95% CI, 1.84–4.16) fold increase of the geometric mean IELT, while after placebo the geometric mean IELT did not increase significantly (1.4-fold increase; 95% CI, 0.84–1.63) (p=0.001). The mean weekly intercourse episodes increased from pretreatment values of 1.16 and 1.14 to 2.2 and 1.4, for dapoxetine and placebo, respectively (p=0.04). Baseline mean intercourse satisfaction domain values of IIEF, 12 and 11, reached to 16 and 10 at the 12-week treatment in groups 1 and 2, respectively (p=0.04). At the end of 3-month follow-up period, the geometric mean IELT in dapoxetine and placebo group demonstrated 1.4- (95% CI, 0.66–1.46) and 1.3- (95% CI, 0.77–1.63) fold increase, respectively (p=0.1). Three-month intercourse satisfaction domain value of IIEF was 11 in group 1 and 10 in group 2 (p=0.1). Mean number of adverse events was 19 for dapoxetine and 7 for placebo (p=0.02). Dapoxetine has moderately better results in terms of IELT and intercourse satisfaction vs placebo without long-term benefit for the patient after it is withdrawn. Further studies are necessary to draw final conclusions on the efficacy of this drug in PE.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Change history
20 February 2023
This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1038/s41386-023-01550-2
References
Ahlenius S, Larsson K, Svensson L, Hjorth S, Carlsson A, Lindberg P et al (1981). Effects of a new type of 5-HT receptor agonist on male rat sexual behavior. Pharmacol Biochem Behav 15: 785–792.
Baldesarani RJ, Mars E (2003). Fluoxetine and side effects. Arch General Psychiatry 47: 191–192.
Byers ES, Grenier G (2003). Premature or rapid ejaculation: heterosexual couples' perceptions of men's ejaculatory behavior. Arch Sex Behav 32: 261–270.
Dresser M, Lindert K, Lin D, Gidwani S, Gupta SK, Modi NB (2004). Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers [abstract]. Clin Pharmacol Ther 75: 113.
Feret B (2005). Focus on dapoxetine: a novel, fast-acting serotonin reuptake inhibitor. Formulary 40: 227–230.
Fisher E (1986). Common sexual problems in general practice. Aust Fam Physician 15: 43–47.
Fleiss J (1986). The Design and Analysis of Clinical Experiments. John Wiley & Sons Inc.: New York, NY, pp 49–51.
Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B (1996). Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung 46: 1029–1036.
Gengo PJ, View M, Giuliano F, McKenna KE, Chester A, Lovenberg T (2005). Monoaminergic transport binding and inhibition profile of dapoxetine, a medication for the treatment of premature ejaculation. J Urol 173 (Suppl): 239. (abstract 878).
Hellstrom WJ, Althof S, Gittelman M, Steidle C, Ho KF, Kell S et al (2005). Dapoxetine for the treatment of men with premature ejaculation (PE): dose-finding analysis. J Urol 173 (Suppl): 238 (abstract 877).
Hellstrom W, Gittelman M, Althof S, Ho KF, Kell S (2004). Dapoxetine HCl for the treatment of premature ejaculation: a phase II, randomized, double-blind, placebo-controlled study. J Sex Med 1 (Suppl): 59. (abstract 097).
Hillegaart V, Ahlenius S (1998). Facilitation and inhibition of male rat ejaculatory behaviour by the respective 5-HT1A and 5-HT1B receptor agonists. Brit J Pharmacol 125: 1733–1743.
Kaplan HS (1974). The New Sex Therapy: Active Treatment of Sexual Dysfunctions. Brunner/Maazel: New York.
Kim SW, Paick JS (1999). Short-term analysis of the effects of as needed use of sertraline at 5 pm for the treatment of premature ejaculation. Urology 54: 544–547.
Laumann EO, Paik A, Rosen RC (1999). Sexual dysfunction in the United States: prevalence and predictors. JAMA 281: 537–544.
Manasia P, Pomerol J, Ribe N, Gutierrez del Pozo R, Alcover Garcia J (2003). Comparison of the efficacy and safety of 90 vs 20 mg fluoxetine in the treatment of premature ejaculation. J Urol 170: 164–165.
Masters WH, Johnson VE (1970). Human Sexual Inadequacy. Little, Brown: Boston, pp 92–142.
McMahon CG (1998). Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 159: 1935–1938.
McMahon CG (2004). Pharmacological treatment of ejaculatory disorders. J Sex Med (Suppl 1): 19–21.
Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S (2006). Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 46: 301–309.
Molewijk HE, van der Heyden JAM, Olivier B (1989). Lower lip retraction is selective mediated by activation of the 5-HT1A receptor. Eur J Neurosci 214 (Suppl 2): 121.
Perelman MA, McMahon CG, Barada JH (2004). Evaluation and treatment of the ejaculatory disorders. In: Lue T (ed). Atlas of Male Sexual Dysfunction. Current Medicine, Inc.: Philadelphia, PA. pp 127–157.
Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Dapoxetine Study Group et al (2006). Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 9: 929–937.
Remy L (1986). The effect of selective 5HT reuptake inhibitors on 5-methoxy-N,N-dimethyltriptamine induced ejaculation in the rat. Br J Pharmacol 87: 639–648.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997). The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49: 822–830.
Rowland DL, Cooper SE, Schneider M (2001). Defining premature ejaculation for experimental and clinical investigations. Arch Sex Behav 30: 235–253.
Sae Chul K, Kyung S (1998). Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 159: 425–427.
Safarinejad MR (2006). Comparison of dapoxetine vs paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin Neuropharmacol 29: 243–252.
Safarinejad MR, Hosseini SY (2006). Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. Int J Impot Res 18: 164–169.
Spector IP, Carey MP (1990). Incidence and prevalence of sexual dysfunctions. A critical review of the empirical literature. Arch Sex Behav 19: 389–408.
Symonds T, Roblin D, Hart K, Althof S (2003). How does premature ejaculation impact a man's life? J Sex Marital Ther 29: 361–370.
Szele FG, Murphy DL, Garrick NA (1988). Effects of fenfluramine, m-chlorophenylpiperazine and other serotonin-related agonists and antagonists on penile erections in non-human primates. Life Sci 43: 1297–1303.
Waldinger MD (2003). Towards evidence-based drug treatment research on premature ejaculation: a critical evaluation of methodology. Int J Impot Res 15: 309–313.
Waldinger MD (2004). Life-long premature ejaculation: from authority based to evidence based medicine. Br J Urol, Int Update Series 93: 201–207.
Waldinger MD, Berendsen HHG, Blok BFM, Olivier B, Holstege G (1998a). Premature ejaculation and serotonergic antidepressant-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 92: 111–118.
Waldinger MD, Hengeveld MW, Zwinderman AH (1994). Paroxetine treatment of premature ejaculation: a double-blind, randomised, placebo-controlled study. Am J Psychiatry 151: 1377–1379.
Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B (1998b). Effect of SSRI antidepressants on ejaculation: a double-blind, randomised, placebo controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline. J Clin Psychopharm 18: 274–281.
Waldinger MD, Zwinderman AH, Olivier B (2001). Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J Clin Psychopharm 21: 293–297.
Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B (2004a). Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 16: 369–381.
Acknowledgements
The investigator is indebted to the patients who participated in this study. We appreciate the encouragement and help provided by coordinators, project managers, and data reviewers. We thank Miss Shiva Safarinejad for her secretarial assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
DISCLOSURE/CONFLICT OF INTEREST
We have no disclosures to report. The author declares that, except for the income received from their primary employer, no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service, and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.
About this article
Cite this article
Safarinejad, M. RETRACTED ARTICLE: Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study. Neuropsychopharmacol 33, 1259–1265 (2008). https://doi.org/10.1038/sj.npp.1301500
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301500
Keywords
This article is cited by
-
The role of dapoxetine hydrochloride on-demand for the treatment of men with premature ejaculation
Scientific Reports (2014)
-
Current Diagnosis and Management of Premature Ejaculation
Current Sexual Health Reports (2014)
